These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1615463)
1. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Potter van Loon BJ; Rijken DC; Brommer EJ; van der Maas AP Thromb Haemost; 1992 Jan; 67(1):101-5. PubMed ID: 1615463 [TBL] [Abstract][Full Text] [Related]
2. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
3. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173 [TBL] [Abstract][Full Text] [Related]
4. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384 [TBL] [Abstract][Full Text] [Related]
5. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis. van Giezen JJ; Boon GI; Jansen JW; Bouma BN Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851 [TBL] [Abstract][Full Text] [Related]
6. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis. Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461 [TBL] [Abstract][Full Text] [Related]
7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541 [TBL] [Abstract][Full Text] [Related]
8. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
9. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424 [TBL] [Abstract][Full Text] [Related]
10. [Local thrombolysis in peripheral arterial occlusion]. Hess H Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076 [TBL] [Abstract][Full Text] [Related]
11. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431 [TBL] [Abstract][Full Text] [Related]
13. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946 [TBL] [Abstract][Full Text] [Related]
15. Diurnal variation of the fibrinolytic system. Grimaudo V; Hauert J; Bachmann F; Kruithof EK Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085 [TBL] [Abstract][Full Text] [Related]
16. Studies on the medical treatment of deep vein thrombosis. Schulman S Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282 [TBL] [Abstract][Full Text] [Related]
17. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels. Nishino N; Scully MF; Rampling MW; Kakkar VV Thromb Haemost; 1990 Dec; 64(4):550-5. PubMed ID: 2128138 [TBL] [Abstract][Full Text] [Related]
18. [rt-PA in extracardiac thromboembolic vascular occlusions]. Cortellaro M; Cofrancesco E; Polli EE Ann Ital Med Int; 1990; 5(1):61-9. PubMed ID: 2119673 [TBL] [Abstract][Full Text] [Related]
19. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
20. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Nishino N; Kakkar VV; Scully MF Thromb Haemost; 1991 Dec; 66(6):672-7. PubMed ID: 1796413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]